Bicycle Therapeutics (BCYC) Competitors

$4.35 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$4.36 +0.02 (+0.34%)

As of 07/2/2026 05:07 PM Eastern

BCYC vs. XNCR, COLL, PURR, MGTX, and ALVO

Should you buy Bicycle Therapeutics stock or one of its competitors? MarketBeat compares Bicycle Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bicycle Therapeutics include Xencor (XNCR), Collegium Pharmaceutical (COLL), Hyperliquid Strategies (PURR), MeiraGTx (MGTX), and Alvotech (ALVO). These companies are all part of the "pharmaceutical products" industry.

How does Bicycle Therapeutics compare to Xencor?

Xencor (NASDAQ:XNCR) and Bicycle Therapeutics (NASDAQ:BCYC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.

86.2% of Bicycle Therapeutics shares are held by institutional investors. 5.1% of Xencor shares are held by insiders. Comparatively, 22.9% of Bicycle Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Xencor has a beta of 0.86, suggesting that its share price is 14% less volatile than the broader market. Comparatively, Bicycle Therapeutics has a beta of 1.55, suggesting that its share price is 55% more volatile than the broader market.

In the previous week, Xencor had 1 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 1 mentions for Xencor and 0 mentions for Bicycle Therapeutics. Xencor's average media sentiment score of 0.75 beat Bicycle Therapeutics' score of 0.00 indicating that Xencor is being referred to more favorably in the media.

Company	Overall Sentiment
Xencor	Positive
Bicycle Therapeutics	Neutral

Xencor currently has a consensus target price of $24.50, indicating a potential upside of 63.33%. Bicycle Therapeutics has a consensus target price of $14.00, indicating a potential upside of 221.84%. Given Bicycle Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Bicycle Therapeutics is more favorable than Xencor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xencor	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44

Xencor has higher revenue and earnings than Bicycle Therapeutics. Xencor is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xencor	$97.36M	11.42	-$91.92M	-$2.29	N/A
Bicycle Therapeutics	$63.50M	4.78	-$218.96M	-$3.15	N/A

Xencor has a net margin of -177.10% compared to Bicycle Therapeutics' net margin of -344.95%. Xencor's return on equity of -28.77% beat Bicycle Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xencor	-177.10%	-28.77%	-20.52%
Bicycle Therapeutics	-344.95%	-35.74%	-29.54%

Summary

Xencor beats Bicycle Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Bicycle Therapeutics compare to Collegium Pharmaceutical?

Collegium Pharmaceutical (NASDAQ:COLL) and Bicycle Therapeutics (NASDAQ:BCYC) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.

Collegium Pharmaceutical has higher revenue and earnings than Bicycle Therapeutics. Bicycle Therapeutics is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Collegium Pharmaceutical	$796.33M	1.51	$62.87M	$2.04	18.15
Bicycle Therapeutics	$63.50M	4.78	-$218.96M	-$3.15	N/A

Collegium Pharmaceutical currently has a consensus price target of $57.50, indicating a potential upside of 55.28%. Bicycle Therapeutics has a consensus price target of $14.00, indicating a potential upside of 221.84%. Given Bicycle Therapeutics' higher probable upside, analysts clearly believe Bicycle Therapeutics is more favorable than Collegium Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Collegium Pharmaceutical	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.17
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44

In the previous week, Collegium Pharmaceutical had 1 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 1 mentions for Collegium Pharmaceutical and 0 mentions for Bicycle Therapeutics. Collegium Pharmaceutical's average media sentiment score of 1.50 beat Bicycle Therapeutics' score of 0.00 indicating that Collegium Pharmaceutical is being referred to more favorably in the media.

Company	Overall Sentiment
Collegium Pharmaceutical	Very Positive
Bicycle Therapeutics	Neutral

Collegium Pharmaceutical has a beta of 0.73, meaning that its share price is 27% less volatile than the broader market. Comparatively, Bicycle Therapeutics has a beta of 1.55, meaning that its share price is 55% more volatile than the broader market.

Collegium Pharmaceutical has a net margin of 9.41% compared to Bicycle Therapeutics' net margin of -344.95%. Collegium Pharmaceutical's return on equity of 95.18% beat Bicycle Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Collegium Pharmaceutical	9.41%	95.18%	16.39%
Bicycle Therapeutics	-344.95%	-35.74%	-29.54%

86.2% of Bicycle Therapeutics shares are owned by institutional investors. 1.9% of Collegium Pharmaceutical shares are owned by insiders. Comparatively, 22.9% of Bicycle Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Collegium Pharmaceutical beats Bicycle Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Bicycle Therapeutics compare to Hyperliquid Strategies?

Bicycle Therapeutics (NASDAQ:BCYC) and Hyperliquid Strategies (NASDAQ:PURR) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment.

Bicycle Therapeutics currently has a consensus target price of $14.00, suggesting a potential upside of 221.84%. Hyperliquid Strategies has a consensus target price of $12.72, suggesting a potential upside of 57.97%. Given Bicycle Therapeutics' higher probable upside, equities research analysts plainly believe Bicycle Therapeutics is more favorable than Hyperliquid Strategies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
Hyperliquid Strategies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Hyperliquid Strategies has a net margin of 0.00% compared to Bicycle Therapeutics' net margin of -344.95%. Bicycle Therapeutics' return on equity of -35.74% beat Hyperliquid Strategies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicycle Therapeutics	-344.95%	-35.74%	-29.54%
Hyperliquid Strategies	N/A	-56.04%	-52.22%

86.2% of Bicycle Therapeutics shares are owned by institutional investors. Comparatively, 9.5% of Hyperliquid Strategies shares are owned by institutional investors. 22.9% of Bicycle Therapeutics shares are owned by company insiders. Comparatively, 8.5% of Hyperliquid Strategies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Hyperliquid Strategies has lower revenue, but higher earnings than Bicycle Therapeutics. Bicycle Therapeutics is trading at a lower price-to-earnings ratio than Hyperliquid Strategies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicycle Therapeutics	$63.50M	4.78	-$218.96M	-$3.15	N/A
Hyperliquid Strategies	$1M	1,162.82	-$16.01M	-$7.37	N/A

Bicycle Therapeutics has a beta of 1.55, meaning that its stock price is 55% more volatile than the broader market. Comparatively, Hyperliquid Strategies has a beta of 1.66, meaning that its stock price is 66% more volatile than the broader market.

In the previous week, Hyperliquid Strategies had 3 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 3 mentions for Hyperliquid Strategies and 0 mentions for Bicycle Therapeutics. Hyperliquid Strategies' average media sentiment score of 0.53 beat Bicycle Therapeutics' score of 0.00 indicating that Hyperliquid Strategies is being referred to more favorably in the news media.

Company	Overall Sentiment
Bicycle Therapeutics	Neutral
Hyperliquid Strategies	Positive

Summary

Bicycle Therapeutics and Hyperliquid Strategies tied by winning 8 of the 16 factors compared between the two stocks.

How does Bicycle Therapeutics compare to MeiraGTx?

Bicycle Therapeutics (NASDAQ:BCYC) and MeiraGTx (NASDAQ:MGTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, media sentiment and analyst recommendations.

MeiraGTx has a net margin of -151.12% compared to Bicycle Therapeutics' net margin of -344.95%. MeiraGTx's return on equity of 0.00% beat Bicycle Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicycle Therapeutics	-344.95%	-35.74%	-29.54%
MeiraGTx	-151.12%	N/A	-54.96%

MeiraGTx has higher revenue and earnings than Bicycle Therapeutics. MeiraGTx is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicycle Therapeutics	$63.50M	4.78	-$218.96M	-$3.15	N/A
MeiraGTx	$79.76M	16.16	-$114.20M	-$1.48	N/A

Bicycle Therapeutics has a beta of 1.55, indicating that its stock price is 55% more volatile than the broader market. Comparatively, MeiraGTx has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market.

86.2% of Bicycle Therapeutics shares are owned by institutional investors. Comparatively, 67.5% of MeiraGTx shares are owned by institutional investors. 22.9% of Bicycle Therapeutics shares are owned by insiders. Comparatively, 7.4% of MeiraGTx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, MeiraGTx had 1 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 1 mentions for MeiraGTx and 0 mentions for Bicycle Therapeutics. MeiraGTx's average media sentiment score of 1.42 beat Bicycle Therapeutics' score of 0.00 indicating that MeiraGTx is being referred to more favorably in the news media.

Company	Overall Sentiment
Bicycle Therapeutics	Neutral
MeiraGTx	Positive

Bicycle Therapeutics presently has a consensus price target of $14.00, indicating a potential upside of 221.84%. MeiraGTx has a consensus price target of $25.83, indicating a potential upside of 85.58%. Given Bicycle Therapeutics' higher possible upside, research analysts plainly believe Bicycle Therapeutics is more favorable than MeiraGTx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
MeiraGTx	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

MeiraGTx beats Bicycle Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Bicycle Therapeutics compare to Alvotech?

Bicycle Therapeutics (NASDAQ:BCYC) and Alvotech (NASDAQ:ALVO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

Bicycle Therapeutics currently has a consensus price target of $14.00, suggesting a potential upside of 221.84%. Alvotech has a consensus price target of $7.60, suggesting a potential upside of 110.53%. Given Bicycle Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Bicycle Therapeutics is more favorable than Alvotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
Alvotech	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Bicycle Therapeutics has a beta of 1.55, indicating that its share price is 55% more volatile than the broader market. Comparatively, Alvotech has a beta of 0.19, indicating that its share price is 81% less volatile than the broader market.

In the previous week, Alvotech had 7 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 7 mentions for Alvotech and 0 mentions for Bicycle Therapeutics. Alvotech's average media sentiment score of 0.79 beat Bicycle Therapeutics' score of 0.00 indicating that Alvotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Bicycle Therapeutics	Neutral
Alvotech	Positive

86.2% of Bicycle Therapeutics shares are held by institutional investors. 22.9% of Bicycle Therapeutics shares are held by insiders. Comparatively, 0.5% of Alvotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Alvotech has a net margin of -14.36% compared to Bicycle Therapeutics' net margin of -344.95%. Alvotech's return on equity of -11.92% beat Bicycle Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicycle Therapeutics	-344.95%	-35.74%	-29.54%
Alvotech	-14.36%	-11.92%	-7.59%

Alvotech has higher revenue and earnings than Bicycle Therapeutics. Alvotech is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicycle Therapeutics	$63.50M	4.78	-$218.96M	-$3.15	N/A
Alvotech	$588.90M	1.85	$27.92M	-$0.25	N/A

Summary

Bicycle Therapeutics and Alvotech tied by winning 8 of the 16 factors compared between the two stocks.

Get Bicycle Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCYC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BCYC vs. The Competition

Export

Metric	Bicycle Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$303.68M	$3.78B	$7.16B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.52%
P/E Ratio	-1.38	21.61	28.02	24.70
Price / Sales	4.78	340.19	540.37	99.46
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	0.49	8.66	10.96	6.46
Net Income	-$218.96M	$23.81M	$3.57B	$337.01M
7 Day Performance	6.10%	3.39%	2.12%	1.69%
1 Month Performance	3.57%	10.81%	5.25%	3.81%
1 Year Performance	-41.41%	62.61%	33.29%	23.90%

Bicycle Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BCYC Bicycle Therapeutics	3.0571 of 5 stars	$4.35 flat	$14.00 +221.8%	-41.4%	$303.68M	$63.50M	N/A	240	Gap Down
XNCR Xencor	1.9324 of 5 stars	$15.68 +0.5%	$24.50 +56.3%	+78.5%	$1.17B	$125.58M	N/A	280	Positive News
COLL Collegium Pharmaceutical	3.4356 of 5 stars	$35.54 -1.2%	$57.50 +61.8%	+21.9%	$1.17B	$780.57M	17.69	210	Positive News
PURR Hyperliquid Strategies	2.6153 of 5 stars	$8.10 -4.3%	$9.25 +14.2%	N/A	$1.17B	$1M	N/A	N/A	News Coverage Analyst Forecast Short Interest Increase Gap Down
MGTX MeiraGTx	2.7995 of 5 stars	$12.91 +3.0%	$25.83 +100.1%	+85.5%	$1.16B	$81.39M	N/A	300	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BCYC) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bicycle Therapeutics (BCYC) Competitors

BCYC vs. XNCR, COLL, PURR, MGTX, and ALVO

How does Bicycle Therapeutics compare to Xencor?

Summary

How does Bicycle Therapeutics compare to Collegium Pharmaceutical?

Summary

How does Bicycle Therapeutics compare to Hyperliquid Strategies?

Summary

How does Bicycle Therapeutics compare to MeiraGTx?

Summary

How does Bicycle Therapeutics compare to Alvotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCYC vs. The Competition

Bicycle Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bicycle Therapeutics (BCYC) Competitors

BCYC vs. XNCR, COLL, PURR, MGTX, and ALVO

How does Bicycle Therapeutics compare to Xencor?

Do institutionals and insiders believe in XNCR or BCYC?

Which has more risk and volatility, XNCR or BCYC?

Does the media refer more to XNCR or BCYC?

Do analysts recommend XNCR or BCYC?

Which has stronger earnings & valuation, XNCR or BCYC?

Is XNCR or BCYC more profitable?

Summary

How does Bicycle Therapeutics compare to Collegium Pharmaceutical?

Which has stronger valuation and earnings, COLL or BCYC?

Do analysts prefer COLL or BCYC?

Does the media refer more to COLL or BCYC?

Which has more volatility and risk, COLL or BCYC?

Is COLL or BCYC more profitable?

Do insiders & institutionals hold more shares of COLL or BCYC?

Summary

How does Bicycle Therapeutics compare to Hyperliquid Strategies?

Do analysts recommend BCYC or PURR?

Is BCYC or PURR more profitable?

Do insiders & institutionals hold more shares of BCYC or PURR?

Which has stronger earnings & valuation, BCYC or PURR?

Which has more volatility & risk, BCYC or PURR?

Does the media prefer BCYC or PURR?

Summary

How does Bicycle Therapeutics compare to MeiraGTx?

Is BCYC or MGTX more profitable?

Which has higher valuation and earnings, BCYC or MGTX?

Which has more volatility and risk, BCYC or MGTX?

Do insiders & institutionals believe in BCYC or MGTX?

Does the media prefer BCYC or MGTX?

Do analysts rate BCYC or MGTX?

Summary

How does Bicycle Therapeutics compare to Alvotech?

Do analysts rate BCYC or ALVO?

Which has more volatility & risk, BCYC or ALVO?

Does the media favor BCYC or ALVO?

Do insiders and institutionals hold more shares of BCYC or ALVO?

Is BCYC or ALVO more profitable?

Which has preferable valuation and earnings, BCYC or ALVO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCYC vs. The Competition

Bicycle Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools